Literature DB >> 19283741

Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas.

S M M de Castro1, S S A Y Biere, S M Lagarde, O R C Busch, T M van Gulik, D J Gouma.   

Abstract

BACKGROUND: Nomograms are statistical tools providing the overall probability of a specific outcome; they have shown better individual discrimination than the tumour node metastasis staging system in several cancers. The pancreatic nomogram, originally developed in the Memorial Sloan-Kettering Cancer Center (MSKCC) in the USA, combines clinicopathological and operative data to predict disease-specific survival at 1, 2 and 3 years from initial resection.
METHODS: An external patient cohort from a retrospective pancreatic adenocarcinoma database at the Academic Medical Centre in Amsterdam was used to test the validity of the pancreatic adenocarcinoma nomogram. The cohort included 263 consecutive patients who had surgery between January 1985 and December 2004.
RESULTS: Data for all the necessary variables were available for 256 patients (97.3 per cent). At the last follow-up, 35 patients were alive, with a median follow-up of 27 (range 3-114) months. The 1-, 2- and 3-year disease-specific survival rates were 60.8, 30.4 and 16.0 per cent respectively. The nomogram concordance index was 0.61. The calibration analysis of the model showed that the predicted survival did not significantly deviate from the actual survival.
CONCLUSION: The MSKCC pancreatic cancer nomogram provided an accurate survival prediction. It may aid in counselling patients and in stratification of patients for clinical trials. (c) 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19283741     DOI: 10.1002/bjs.6548

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  17 in total

1.  Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma?

Authors:  Linda M Pak; Mithat Gonen; Kenneth Seier; Vinod P Balachandran; Michael I D'Angelica; William R Jarnagin; T Peter Kingham; Peter J Allen; Richard K G Do; Amber L Simpson
Journal:  Abdom Radiol (NY)       Date:  2018-08

2.  A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.

Authors:  May Piperdi; Theodore P McDade; Joon K Shim; Bilal Piperdi; Sidney P Kadish; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

3.  Sociodemographics and comorbidities influence decisions to undergo pancreatic resection for neoplastic lesions.

Authors:  Charbel Sandroussi; Chantelle Brace; Erin D Kennedy; Nancy N Baxter; Steven Gallinger; Alice C Wei
Journal:  J Gastrointest Surg       Date:  2010-06-23       Impact factor: 3.452

4.  Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score.

Authors:  Sinziana Dumitra; Mohammad H Jamal; Jad Aboukhalil; Suhail A Doi; Prosanto Chaudhury; Mazen Hassanain; Peter P Metrakos; Jeffrey S Barkun
Journal:  HPB (Oxford)       Date:  2013-03-22       Impact factor: 3.647

5.  Development and validation of a novel nomogram for predicting the prognosis of patients with resected pancreatic adenocarcinoma.

Authors:  Hu Ren; Chao-Rui Wu; Saderbieke Aimaiti; Cheng-Feng Wang
Journal:  Oncol Lett       Date:  2020-03-29       Impact factor: 2.967

6.  Multi-institutional development and external validation of machine learning-based models to predict relapse risk of pancreatic ductal adenocarcinoma after radical resection.

Authors:  Xiawei Li; Litao Yang; Zheping Yuan; Jianyao Lou; Yiqun Fan; Aiguang Shi; Junjie Huang; Mingchen Zhao; Yulian Wu
Journal:  J Transl Med       Date:  2021-06-30       Impact factor: 5.531

7.  Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient group.

Authors:  Daniel Habermehl; Ingo C Brecht; Jürgen Debus; Stephanie E Combs
Journal:  Eur J Med Res       Date:  2014-05-13       Impact factor: 2.175

8.  Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.

Authors:  Xiwen Liao; Ketuan Huang; Rui Huang; Xiaoguang Liu; Chuangye Han; Long Yu; Tingdong Yu; Chengkun Yang; Xiangkun Wang; Tao Peng
Journal:  Onco Targets Ther       Date:  2017-09-12       Impact factor: 4.147

9.  Proposal of a modified American Joint Committee on Cancer staging scheme for resectable pancreatic ductal adenocarcinoma with a lymph node ratio-based N classification: A retrospective cohort study.

Authors:  Huan-Jun Li; Yu-Tong Chen; Shu-Qiang Yuan
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

10.  Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer.

Authors:  Stephan B Dreyer; Mark Pinese; Nigel B Jamieson; Christopher J Scarlett; Emily K Colvin; Marina Pajic; Amber L Johns; Jeremy L Humphris; Jianmin Wu; Mark J Cowley; Angela Chou; Adnan M Nagrial; Lorraine Chantrill; Venessa T Chin; Marc D Jones; Kim Moran-Jones; Christopher Ross Carter; Euan J Dickson; Jaswinder S Samra; Neil D Merrett; Anthony J Gill; James G Kench; Fraser Duthie; David K Miller; Susanna Cooke; Daniela Aust; Thomas Knösel; Petra Rümmele; Robert Grützmann; Christian Pilarsky; Nam Q Nguyen; Elizabeth A Musgrove; Peter J Bailey; Colin J McKay; Andrew V Biankin; David K Chang
Journal:  Ann Surg       Date:  2020-08       Impact factor: 13.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.